Redox biology

The Pan African medical journal

Journal of veterinary internal medicine

european heart journal cardiovascular imaging

[1] Histoplasmosis, heart failure, hemolysis and haemophagocytic lymphohistiocytosis.

[2] A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis.

[3] ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.

[4] Specific O-GlcNAc modification at Ser-615 modulates eNOS function.

[5] pulmonary arterial hypertension in russia: six-year observation analysis of the national registry

[6] effects of an 8-month exercise intervention on physical capacity, nt-probnp, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by nyha class

[7] hyperthyroidism with pulmonary hypertension for emergency caesarean section – a rare case

[8] effect of oral nitrate supplementation on pulmonary hemodynamics during exercise and time trial performance in normoxia and hypoxia: a randomized controlled trial

[9] elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension

[10] self-reported physician practices in pulmonary arterial hypertension: diagnosis, assessment, and referral

[11] comparative transcriptome analysis identifies ccdc80 as a novel gene associated with pulmonary arterial hypertension

[12] Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

[13] Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

[14] Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.

[15] A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis.

[16] Current and future treatments of pulmonary arterial hypertension.

[17] Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension

[18] increased drp1-mediated mitochondrial fission promotes proliferation and collagen production by right ventricular fibroblasts in experimental pulmonary arterial hypertension

[19] polymorphism of the fractalkine receptor cx3cr1 and systemic sclerosis-associated pulmonary arterial hypertension

[20] pulmonary arterial hypertension in russia: six-year observation analysis of the national registry

[21] exercise intolerance in pulmonary arterial hypertension

[22] effects of an 8-month exercise intervention on physical capacity, nt-probnp, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by nyha class

[23] assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of canadian pulmonary hypertension physicians

[24] elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension

[25] self-reported physician practices in pulmonary arterial hypertension: diagnosis, assessment, and referral

[26] the correlation of decreased heart rate recovery and chronotropic incompetence with exercise capacity in idiopathic pulmonary arterial hypertension patients

[27] biomarkers for pediatric pulmonary arterial hypertension – a call to collaborate

[28] comparative transcriptome analysis identifies ccdc80 as a novel gene associated with pulmonary arterial hypertension

[29] prognostication in pulmonary arterial hypertension with submaximal exercise testing

[30] short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension

[31] critérios prognósticos em hipertensão arterial pulmonar prognostic markers in pulmonary arterial hypertension

[32] hipertensão arterial pulmonar: fisiopatologia, aspectos genéticos e resposta ao uso crônico do sildenafil pulmonary arterial hypertension: physiopathology, genetic aspects and response to the chronic use of sildenafil

[33] uso crônico de decanoato de nandrolona como fator de risco para hipertensão arterial pulmonar em ratos wistar chronic use of nandrolone decanoate as risk factor for pulmonary arterial hypertension in wistar rats